Page last updated: 2024-08-21

indazoles and Obesity

indazoles has been researched along with Obesity in 12 studies

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (33.33)29.6817
2010's7 (58.33)24.3611
2020's1 (8.33)2.80

Authors

AuthorsStudies
Lai, Q; Li, W; Lou, J; Peng, C; Teng, Z; Xu, C; Yin, L; Zhang, C; Zhou, X1
Antunes, E; Mónica, FZ1
Guzzo, PR; Moore, NA; Sargent, BJ; Surman, MD1
Aida, J; Hotta, N; Igawa, H; Ikoma, M; Kakegawa, K; Kaku, H; Kasai, S; Kawata, Y; Kina, A; Maekawa, T; Nagisa, Y; Nakayama, M; Noguchi, T; Okuda, S; Takahashi, M; Yamamoto, S1
Cheruvallath, Z; Dougan, DR; Erikson, P; Farrell, P; Feng, J; Holub, C; Komandla, M; Larson, C; Lawson, JD; McBride, C; Miura, J; Plonowski, A; Tang, M; Ton-Nu, T; Vanderpool, D; Wu, Y1
Cheetham, S; Freeman, EE; Grabowski, JF; Guzzo, PR; Hadden, M; Henderson, AJ; Jiang, G; Jiang, XM; Khmelnitsky, Y; Luche, M; Surman, MD; Vickers, S; Viggers, J1
Lazzari, P; Mastinu, A; Pani, L; Pinna, GA; Pira, M1
Choi, SE; Han, SJ; Hwang, YC; Jeoung, K; Jung, IR; Jung, JG; Kang, Y; Kim, DJ; Kim, HJ; Ku, JM; Lee, KW; Lee, SJ; Yi, SA1
Hayashi, A; Kimura, Y; Miyata, K; Sasamata, M; Sonoda, R; Suzuki, M; Takasu, T1
Brodjian, S; Brune, M; Bush, E; Collins, CA; Dayton, B; Gao, J; Hernandez, LE; Judd, AS; Kym, PR; Marsh, KC; Mulhern, M; Sham, HL; Shapiro, R; Souers, AJ; Vasudevan, A; Wodka, D1
Brodjian, SJ; Brune, ME; Bush, EN; Collins, CA; Dayton, BD; Gao, J; Hernandez, LE; Judd, AS; Kym, PR; Marsh, KC; Mulhern, MM; Napier, JJ; Sham, HL; Shapiro, R; Souers, AJ; Wodka, D1
Johns, EJ; Wongmekiat, O1

Reviews

2 review(s) available for indazoles and Obesity

ArticleYear
Stimulators and activators of soluble guanylate cyclase for urogenital disorders.
    Nature reviews. Urology, 2018, Volume: 15, Issue:1

    Topics: Aging; Animals; Benzoates; Diabetes Complications; Enzyme Activators; Humans; Hypertension; Indazoles; Lower Urinary Tract Symptoms; Nitric Oxide; Obesity; Phosphodiesterase 5 Inhibitors; Pyrazoles; Pyridines; Reactive Oxygen Species; Risk Factors; Soluble Guanylyl Cyclase; Urinary Tract

2018
From preclinical to clinical development: the example of a novel treatment for obesity.
    Neurobiology of disease, 2014, Volume: 61

    Topics: Animals; Anti-Obesity Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Humans; Indazoles; Male; Obesity; Pyridones; Rats; Receptors, Pituitary Hormone

2014

Other Studies

10 other study(ies) available for indazoles and Obesity

ArticleYear
Prevention of Obesity Related Diseases through Laminarin-induced targeted delivery of Bindarit.
    Theranostics, 2020, Volume: 10, Issue:21

    Topics: Adipose Tissue; Animals; Atherosclerosis; Computer Simulation; Diet, High-Fat; Fatty Liver; Glucans; Humans; Indazoles; Inflammation; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Monocytes; Nanoparticles; Obesity; Plaque, Atherosclerotic; Propionates

2020
Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test.
    Bioorganic & medicinal chemistry, 2016, 06-01, Volume: 24, Issue:11

    Topics: Animals; Anti-Obesity Agents; Dose-Response Relationship, Drug; Humans; Indazoles; Male; Molecular Structure; Obesity; Pyridones; Rats; Rats, Inbred F344; Receptors, Somatostatin; Structure-Activity Relationship

2016
Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1.
    Bioorganic & medicinal chemistry letters, 2016, Jun-15, Volume: 26, Issue:12

    Topics: Administration, Oral; Aminopeptidases; Animals; Body Weight; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Glycoproteins; Humans; Indazoles; Methionyl Aminopeptidases; Mice; Mice, Obese; Models, Molecular; Molecular Structure; Obesity; Structure-Activity Relationship

2016
5-(pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists.
    Bioorganic & medicinal chemistry letters, 2010, Dec-01, Volume: 20, Issue:23

    Topics: Animals; Anti-Obesity Agents; Cardiovascular Diseases; Ether-A-Go-Go Potassium Channels; Humans; Indazoles; Mice; Obesity; Receptors, Pituitary Hormone; Structure-Activity Relationship

2010
NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
    Behavioural brain research, 2012, Oct-01, Volume: 234, Issue:2

    Topics: Analysis of Variance; Animals; Anti-Obesity Agents; Blood Glucose; Body Mass Index; Body Weight; Brain-Derived Neurotrophic Factor; Cannabinoid Receptor Antagonists; Cholesterol; Dietary Fats; Disease Models, Animal; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Hypothalamus; Indazoles; Intra-Abdominal Fat; Liver; Male; Mice; Mice, Inbred C57BL; Nerve Growth Factor; Obesity; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Serotonin Plasma Membrane Transport Proteins; Thiophenes; Transaminases; Triglycerides

2012
A compound (DW1182v) protecting high glucose/palmitate-induced glucolipotoxicity to INS-1 beta cells preserves islet integrity and improves hyperglycemia in obese db/db mouse.
    European journal of pharmacology, 2012, Dec-05, Volume: 696, Issue:1-3

    Topics: Animals; Blood Glucose; Cell Line; Cell Survival; Endoplasmic Reticulum Stress; Glucose; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Indazoles; Insulin; Insulin-Secreting Cells; Male; Mice; Mice, Obese; Obesity; Palmitates; Pyrimidines

2012
Antiobesity effect of YM348, a novel 5-HT2C receptor agonist, in Zucker rats.
    Brain research, 2004, Jun-18, Volume: 1011, Issue:2

    Topics: Aminopyridines; Animals; Anti-Obesity Agents; Blood Glucose; Body Temperature; Body Weight; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Eating; Energy Intake; Indazoles; Indoles; Insulin; Lipids; Male; Obesity; Rats; Rats, Zucker; Serotonin 5-HT2 Receptor Agonists; Serotonin Antagonists; Time Factors; Weight Gain

2004
Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.
    Journal of medicinal chemistry, 2005, Mar-10, Volume: 48, Issue:5

    Topics: Acetamides; Administration, Oral; Animals; Anti-Obesity Agents; Binding, Competitive; Brain; Calcium; Chronic Disease; Indazoles; Mice; Obesity; Pyrrolidines; Radioligand Assay; Receptors, Somatostatin; Structure-Activity Relationship; Tissue Distribution

2005
Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; Indazoles; Mice; Obesity; Receptors, Somatostatin; Structure-Activity Relationship; Urea

2005
Interactions between nitric oxide and renal nerves in the excretion of a saline load in obese Zucker rats.
    Clinical science (London, England : 1979), 2001, Volume: 101, Issue:3

    Topics: Animals; Blood Glucose; Diuresis; Enzyme Inhibitors; Guanidines; Hemodynamics; Indazoles; Kidney; Male; Natriuresis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Obesity; Rats; Rats, Zucker

2001